Genmab, Inc. Sells Arzerra Co-Promotion Rights to GlaxoSmithKline; Genmab will Receive a One-time Payment of $4.5M from GSK Upon the FDA’s Acceptance for Review of the Filing of the First BLA for Ofatumumab

December 18, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

COPENHAGEN, Denmark, Dec. 18, 2008 (GLOBE NEWSWIRE) -- Summary: Genmab announces an amendment to its worldwide agreement with GSK to co-develop and commercialize Arzerra.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions Europe

GlaxoSmithKline Food and Drug Administration (FDA)